Zosurabalpin

Zosurabalpin
Sonraí cliniciúla
Grúpa cógaseolaíochta	comhdhúil cheimiceach
Sonraí ceimiceacha agus fisiceacha
Foirmle	C43H50N8O5S
Mais mhóilíneach	790.3624877 Da
Uimhir CAS	2379336-76-0
PubChem (SID)	148636827
UNII	5Y6W5N1U0S

Is antaibheathach turgnamhach é Zosurabalpin ( RG6006, Abx-MCP, Ro7223280 ) a forbraíodh i gcomhoibriú idir an chuideachta cógaisíochta Roche agus eolaithe ó Ollscoil Harvard, le haghaidh cóireáil Acinetobacter baumannii (CRAB) a bhfuil frithsheasamh in aghaidh carbapenem. Díríonn sé ar iompróir lipeapolaisiúicríde (LPS) . ^[1] Oibríonn sé trí láthair an nasctha ilchodach a aithint, atá comhdhéanta den iompróir Lpt agus dá shubstráití LPS. ^[2] Nochtadh an fhine cheimiceach lena mbaineann sé den chéad uair sa bhliain 2019, ach d'fhan struchtúr áirithe de RG6006 faoi rún go dtí gur foilsíodh torthaí na tástála sa bhliain 2023. ^[3] ^[4]

Féach freisin

Clovibaictin
Novobiocin
Teixobactin

Tagairtí

↑ "A novel antibiotic class targeting the lipopolysaccharide transporter" (January 2024). Nature 625 (7995): 566–571. doi:10.1038/s41586-023-06873-0. PMID 38172634.
↑ "A new antibiotic traps lipopolysaccharide in its intermembrane transporter" (January 2024). Nature 625 (7995): 572–577. doi:10.1038/s41586-023-06799-7. PMID 38172635.
↑ "Open Forum Infectious Diseases" (December 2023) 10 (Suppl 2). Oxford University Press. doi:10.1093/ofid/ofad500.1733.
↑ "Evaluating the innovative potential of the global antibacterial pipeline" (October 2023). Clinical Microbiology and Infection. doi:10.1016/j.cmi.2023.09.024. PMID 37805036.

[pmid38172634-1] "A novel antibiotic class targeting the lipopolysaccharide transporter" (January 2024). Nature 625 (7995): 566–571. doi:10.1038/s41586-023-06873-0. PMID 38172634.

[2] "A new antibiotic traps lipopolysaccharide in its intermembrane transporter" (January 2024). Nature 625 (7995): 572–577. doi:10.1038/s41586-023-06799-7. PMID 38172635.

[3] "Open Forum Infectious Diseases" (December 2023) 10 (Suppl 2). Oxford University Press. doi:10.1093/ofid/ofad500.1733.

[pmid37805036-4] "Evaluating the innovative potential of the global antibacterial pipeline" (October 2023). Clinical Microbiology and Infection. doi:10.1016/j.cmi.2023.09.024. PMID 37805036.

[1]

[2]

[3]

[4]